Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma

Experimental Eye Research

Volumn 86, Issue 2, 2008, Pages 201-206

  Cohen, Yoram ^c   Merhavi Shoham, Efrat ^a,b   Avraham, Revital B ^a   Frenkel, Shahar ^d   Pe'er, Jacob ^d   Goldenberg Cohen, Nitza ^a,e  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

BRAF mutations; CIMP; CpG island methylator phenotype; epigenetic silencing; methylation status; RASSF1A; retinoblastoma; tumor suppressor genes

Indexed keywords

B RAF KINASE; BISULFITE; CALCIUM CHANNEL T TYPE; DEATH ASSOCIATED PROTEIN KINASE; NEUROGENIN 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; SOMATOMEDIN B; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; GENE LOCUS; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN TISSUE; METHYLATION; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EPIGENESIS, GENETIC; GENE SILENCING; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 39149123532     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2007.10.010     Document Type: Article

References (41)

1. Bautista D., Emanuel J.R., Granville C., Howard R., and Costa J. Identification of mutations in the Ki-ras gene in human retinoblastoma. Investig. Ophthalmol. Vis. Sci. 37 (1996) 2313-2317
2. Bookstein R., and Lee W.H. Molecular genetics of the retinoblastoma suppressor gene. Crit. Rev. Oncog. 2 (1991) 211-227
3. Chau B.N., and Wang J.Y. Coordinated regulation of life and death by RB. Nat. Rev. Cancer 3 (2003) 130-138
4. Choy K.W., Lee T.C., Cheung K.F., Fan D.S., Lo K.W., Beaverson K.L., Abramson D.H., Lam D.S., Yu C.B., and Pang C.P. Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma. Neoplasia 7 (2005) 200-206
5. Choy K.W., Pang C.P., To K.F., Yu C.B., Ng J.S., and Lam D.S. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues. Investig. Ophthalmol. Vis. Sci. 43 (2002) 1344-1349
6. Choy K.W., Pang C.P., Yu C.B., Wong H.L., Ng J.S., Fan D.S., Lo K.W., Chai J.T., Wang J., Fu W., and Lam D.S. Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese with sporadic retinoblastoma. Hum. Mutat. 20 (2002) 408
7. Cohen Y., Goldenberg-Cohen N., Parrella P., Chowers I., Merbs S.L., Pe'er J., and Sidransky D. Lack of BRAF mutation in primary uveal melanoma. Investig. Ophthalmol. Vis. Sci. 44 (2003) 2876-2878
8. Cohen Y., Rosenbaum E., Begum S., Goldenberg D., Esche C., Lavie O., Sidransky D., and Westra W.H. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin. Cancer Res. 10 (2004) 3444-3447
9. Cohen Y., Singer G., Lavie O., Dong S.M., Beller U., and Sidransky D. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin. Cancer Res. 9 (2003) 2981-2984
10. Corson T.W., and Gallie B.L. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 46 (2007) 617-634
11. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
12. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
13. Draper G.J., Sanders B.M., and Kingston J.E. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer 53 (1986) 661-671
14. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., Danenberg P.V., and Laird P.W. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28 (2000) E32
15. Edwards R.H., Ward M.R., Wu H., Medina C.A., Brose M.S., Volpe P., Nussen-Lee S., Haupt H.M., Martin A.M., Herlyn M., Lessin S.R., and Weber B.L. Absence of BRAF mutations in UV-protected mucosal melanomas. J. Med. Genet. 41 (2004) 270-272
16. Gouyer V., Gazzeri S., Bolon I., Drevet C., Brambilla C., and Brambilla E. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am. J. Respir. Cell Mol. Biol. 18 (1998) 188-196
17. Greger V., Debus N., Lohmann D., Hopping W., Passarge E., and Horsthemke B. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. Hum. Genet. 94 (1994) 491-496
18. Harada K., Toyooka S., Maitra A., Maruyama R., Toyooka K.O., Timmons C.F., Tomlinson G.E., Mastrangelo D., Hay R.J., Minna J.D., and Gazdar A.F. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21 (2002) 4345-4349
19. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 9700-9704
20. Jacinto F.V., and Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis (2007)
21. Joseph B., Mamatha G., Raman G., Shanmugam M.P., and Kumaramanickavel G. Methylation status of RB1 promoter in Indian retinoblastoma patients. Cancer Biol. Ther. 3 (2004) 184-187
22. Kohonen-Corish M.R., Sigglekow N.D., Susanto J., Chapuis P.H., Bokey E.L., Dent O.F., Chan C., Lin B.P., Seng T.J., Laird P.W., Young J., Leggett B.A., Jass J.R., and Sutherland R.L. Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene (2007)
23. Lee W.H., Bookstein R., Hong F., Young L.J., Shew J.Y., and Lee E.Y. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235 (1987) 1394-1399
24. Lillington D.M., Kingston J.E., Coen P.G., Price E., Hungerford J., Domizio P., Young B.D., and Onadim Z. Comparative genomic hybridization of 49 primary retinoblastoma tumors identifies chromosomal regions associated with histopathology, progression, and patient outcome. Genes Chromosomes Cancer 36 (2003) 121-128
25. MacCarthy A., Draper G.J., Steliarova-Foucher E., and Kingston J.E. Retinoblastoma incidence and survival in European children (1978-1997). Report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 42 (2006) 2092-2102
26. Merbs S.L., and Sidransky D. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Investig. Ophthalmol. Vis. Sci. 40 (1999) 779-783
27. Merhavi E., Cohen Y., Avraham B.C., Frenkel S., Chowers I., Pe'er J., and Goldenberg-Cohen N. Promoter methylation status of multiple genes in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 48 (2007) 4403-4406
28. Michaloglou C., Vredeveld L.C., Mooi W.J., and Peeper D.S. BRAF(E600) in benign and malignant human tumours. Oncogene (2007)
29. Minoo P., Moyer M., and Jass J. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J. Pathol. (2007)
30. Moll A.C., Imhof S.M., Schouten-Van Meeteren A.Y., Kuik D.J., Hofman P., and Boers M. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk?. Ophthalmology 108 (2001) 1109-1114
31. Morrissey C., Martinez A., Zatyka M., Agathanggelou A., Honorio S., Astuti D., Morgan N.V., Moch H., Richards F.M., Kishida T., Yao M., Schraml P., Latif F., and Maher E.R. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 61 (2001) 7277-7281
32. Parkin D.M., Stiller C.A., Draper G.J., and Bieber C.A. The international incidence of childhood cancer. Int. J. Cancer 42 (1988) 511-520
33. Pfeifer G.P., Yoon J.H., Liu L., Tommasi S., Wilczynski S.P., and Dammann R. Methylation of the RASSF1A gene in human cancers. Biol. Chem. 383 (2002) 907-914
34. Pieretti M., Powell D.E., Gallion H.H., Conway P.S., Case E.A., and Turker M.S. Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer. Hum. Pathol. 26 (1995) 398-401
35. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
36. Sampieri K., Hadjistilianou T., Mari F., Speciale C., Mencarelli M.A., Cetta F., Manoukian S., Peissel B., Giachino D., Pasini B., Acquaviva A., Caporossi A., Frezzotti R., Renieri A., and Bruttini M. Mutational screening of the RB1 gene in Italian patients with retinoblastoma reveals 11 novel mutations. J. Hum. Genet. 51 (2006) 209-216
37. TrimGen. mol. 'Genetic Technology' Mutector (2003). http://www.trimgen.com/mutector.htm Available from:
38. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Widschwendter M., Weener D., Buchanan D., Koh H., Simms L., Barker M., Leggett B., Levine J., Kim M., French A.J., Thibodeau S.N., Jass J., Haile R., and Laird P.W. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38 (2006) 787-793
39. Xing M., Cohen Y., Mambo E., Tallini G., Udelsman R., Ladenson P.W., and Sidransky D. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer. Res. 64 (2004) 1664-1668
40. Yates D.R., Rehman I., Abbod M.F., Meuth M., Cross S.S., Linkens D.A., Hamdy F.C., and Catto J.W. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 13 (2007) 2046-2053
41. Zhu J., and Yao X. Use of DNA methylation for cancer detection and molecular classification. J. Biochem. Mol. Biol. 40 (2007) 135-141